The Protein Can Also Treat Diabetes Without Insulin
Diabetes is a chronic disease, affecting more than 460 million people worldwide. With the change of life and eating habits, diabetes has become the third major factor affecting human health after cardiovascular and cerebrovascular diseases and malignant tumors. In China, there are more than 114 million adults with diabetes, accounting for one quarter of the world's diabetes patients.
Diabetes can induce a series of complications, such as cardiovascular disease and kidney disease, which seriously affect human health. At present, insulin therapy is the main means to control blood sugar.
Recently, Professor Roberto coppari of the diabetes center of the medical school of the University of Geneva, Switzerland, published a research paper entitled "hematopoietic non parental s100a9-tlr4-mtorc1 axis normalizes diabetic ketogenesis" in the journal "nature communications".
This study reported an insulin independent approach to treat diabetes, a protein called S100A9, which can regulate blood glucose, lipids and ketones, and has no side effects of insulin. It has the potential to replace insulin, thereby reducing the risk of adverse side effects.
People with severe diabetes, pancreatic β The cells cannot produce enough insulin. In order to survive, patients can only inject insulin to themselves regularly. But insulin treatment also has side effects, on the one hand, it is difficult to give drugs. On the other hand, in the long run, it may also lead to serious metabolic and cardiovascular problems. If the dosage is too high or too low, it may even directly lead to some potential fatal risks, including fatal hypoglycemia, negative effects on fat metabolism and elevated cholesterol.
Therefore, it is particularly important to find a replacement therapy for insulin.
As early as 2019, Professor Coppari found S100A9 protein, which can regulate blood glucose, lipids and ketone bodies, and has no side effects of insulin. However, in order to develop drugs, researchers must understand how precisely this protein works and demonstrate its effectiveness in animal models.
In this study, researchers created a diabetes mouse model, injected S100A9 into mice, and analyzed the action mode of S100A9 in diabetes mice.
It has been found that S100A9 plays a role in the liver. It can activate TLR4 receptors on some cell membranes, but it does not activate liver cells.
The researchers said that from a pharmacological point of view, this is a good news, which means S100A9 can play its role without entering liver cells, and allows simple injection administration.
In addition, the study also found that the activation of TLR4 in the liver controls the production of ketones, and TLR4 is usually proinflammatory, but this activation process does not trigger inflammation. Therefore, S100A9 activation of TLR4 receptor seems to be a completely unexpected anti-inflammatory drug.
In order to further verify the research results, the researchers conducted an observational clinical study to collect the plasma S100A9 content of decompensated diabetes patients and healthy controls.
As expected, all patients suffered from hyperglycemia and hyperketosis. Compared with healthy subjects, the study found a slight increase in the content of S100A9 in the circulation, which is consistent with the findings in the mouse model. Therefore, additional S100A9 administration is expected to enhance this compensation mechanism.
The researchers said that previous studies focused on drugs that increase insulin sensitivity, but this would only lead to the same results at lower doses, and the side effects of insulin treatment remained unchanged. The study proposed a completely different strategy, using a drug that works independently of insulin, which will neither cause hypoglycemia nor destroy fat metabolism.
In conclusion, the study found that S100A9 protein has the potential to replace insulin demand, thereby reducing the risk of adverse side effects and improving metabolic control.
At present, Wuxi Donglin Science and Technology Development Co., Ltd. has developed a variety of Elisa products for the above mentioned proteins. If you want to know about relevant Elisa reagents, you can directly visit the website:
S100 calcium binding protein A9 (S100A9)
http://www.dldevelop.com/research-reagent/DL-S100A9-b.html
https://www.dldevelop.com/research-reagent/DL-S100A9-Hu.html
http://www.dldevelop.com/research-reagent/DL-S100A9-Mu.html
Toll-like receptor 4(TLR4)
http://www.dldevelop.com/research-reagent/DL-TLR4-b.html
http://www.dldevelop.com/research-reagent/DL-TLR4-Hu.html
http://www.dldevelop.com/research-reagent/DL-TLR4-Mu.html
http://www.dldevelop.com/research-reagent/DL-TLR4-Ra.html
Diabetes can induce a series of complications, such as cardiovascular disease and kidney disease, which seriously affect human health. At present, insulin therapy is the main means to control blood sugar.
Recently, Professor Roberto coppari of the diabetes center of the medical school of the University of Geneva, Switzerland, published a research paper entitled "hematopoietic non parental s100a9-tlr4-mtorc1 axis normalizes diabetic ketogenesis" in the journal "nature communications".
This study reported an insulin independent approach to treat diabetes, a protein called S100A9, which can regulate blood glucose, lipids and ketones, and has no side effects of insulin. It has the potential to replace insulin, thereby reducing the risk of adverse side effects.
People with severe diabetes, pancreatic β The cells cannot produce enough insulin. In order to survive, patients can only inject insulin to themselves regularly. But insulin treatment also has side effects, on the one hand, it is difficult to give drugs. On the other hand, in the long run, it may also lead to serious metabolic and cardiovascular problems. If the dosage is too high or too low, it may even directly lead to some potential fatal risks, including fatal hypoglycemia, negative effects on fat metabolism and elevated cholesterol.
Therefore, it is particularly important to find a replacement therapy for insulin.
As early as 2019, Professor Coppari found S100A9 protein, which can regulate blood glucose, lipids and ketone bodies, and has no side effects of insulin. However, in order to develop drugs, researchers must understand how precisely this protein works and demonstrate its effectiveness in animal models.
In this study, researchers created a diabetes mouse model, injected S100A9 into mice, and analyzed the action mode of S100A9 in diabetes mice.
It has been found that S100A9 plays a role in the liver. It can activate TLR4 receptors on some cell membranes, but it does not activate liver cells.
The researchers said that from a pharmacological point of view, this is a good news, which means S100A9 can play its role without entering liver cells, and allows simple injection administration.
In addition, the study also found that the activation of TLR4 in the liver controls the production of ketones, and TLR4 is usually proinflammatory, but this activation process does not trigger inflammation. Therefore, S100A9 activation of TLR4 receptor seems to be a completely unexpected anti-inflammatory drug.
In order to further verify the research results, the researchers conducted an observational clinical study to collect the plasma S100A9 content of decompensated diabetes patients and healthy controls.
As expected, all patients suffered from hyperglycemia and hyperketosis. Compared with healthy subjects, the study found a slight increase in the content of S100A9 in the circulation, which is consistent with the findings in the mouse model. Therefore, additional S100A9 administration is expected to enhance this compensation mechanism.
The researchers said that previous studies focused on drugs that increase insulin sensitivity, but this would only lead to the same results at lower doses, and the side effects of insulin treatment remained unchanged. The study proposed a completely different strategy, using a drug that works independently of insulin, which will neither cause hypoglycemia nor destroy fat metabolism.
In conclusion, the study found that S100A9 protein has the potential to replace insulin demand, thereby reducing the risk of adverse side effects and improving metabolic control.
At present, Wuxi Donglin Science and Technology Development Co., Ltd. has developed a variety of Elisa products for the above mentioned proteins. If you want to know about relevant Elisa reagents, you can directly visit the website:
S100 calcium binding protein A9 (S100A9)
http://www.dldevelop.com/research-reagent/DL-S100A9-b.html
https://www.dldevelop.com/research-reagent/DL-S100A9-Hu.html
http://www.dldevelop.com/research-reagent/DL-S100A9-Mu.html
Toll-like receptor 4(TLR4)
http://www.dldevelop.com/research-reagent/DL-TLR4-b.html
http://www.dldevelop.com/research-reagent/DL-TLR4-Hu.html
http://www.dldevelop.com/research-reagent/DL-TLR4-Mu.html
http://www.dldevelop.com/research-reagent/DL-TLR4-Ra.html
